Ledertrexate

Methotrexate Disodium, the active ingredient in Ledertrexate, is an antimetabolite (folate antagonist) presented as a sterile injectable solution for intraarterial, intracardiac and intramuscular use. It treats rheumatoid arthritis, psoriasis, selected malignancies and ectopic pregnancy in appropriately selected patients.

GNH USA supplies Ledertrexate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ledertrexate, a folate‑antagonist antimetabolite, is employed across several disease families where rapid cell proliferation is a hallmark. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: improves skin lesions and decreases scaling. - Acute lymphoblastic leukemia: induces remission by inhibiting malignant lymphoblast proliferation. - Lymphoma: contributes to tumor control and disease stabilization. - Ectopic pregnancy: terminates trophoblastic tissue to prevent complications.

Adverse reactions vary with dose, route and patient factors.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Mild elevation of liver enzymes.

Serious or Rare Side Effects: - Severe hepatic toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Bone marrow suppression leading to pancytopenia. - Acute renal failure or nephrotoxicity. - Anaphylactic or severe hypersensitivity reactions. - Life‑threatening infections due to immunosuppression.

Careful monitoring and patient education are essential when using Ledertrexate. - Liver function monitoring: perform baseline and periodic liver enzyme tests. - Hematologic monitoring: check complete blood counts regularly. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Renal function assessment: adjust dose in patients with impaired clearance. - Drug‑specific counseling: advise patients to report signs of infection or respiratory difficulty promptly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate Disodium has several clinically relevant drug interactions.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Sulfonamide antibiotics: potentiate hematologic suppression. - Live attenuated vaccines: risk of severe infection. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Azathioprine or other immunosuppressants: enhanced immunosuppression. - Cyclosporine: may increase methotrexate levels. - Warfarin: potential for increased anticoagulant effect. - Oral contraceptives: may reduce methotrexate efficacy.